SaOS-2Homo sapiens (Human)Cancer cell line
Also known as: SAOS-2, Saos-2, SAOS 2, Saos 2, Saos2, SaOs2, SAOS2, Sarcoma OSteogenic-2, SaOS, SAOS
Quick Overview
Human osteosarcoma cell line with known genetic and epigenetic alterations.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_0548 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Bone[UBERON:UBERON_0002481] |
Donor Information
| Age | 11 |
|---|---|
| Age Category | Pediatric |
| Sex | Female |
| Race | caucasian |
Disease Information
| Disease | Osteosarcoma |
|---|---|
| Lineage | Bone |
| Subtype | Osteosarcoma |
| OncoTree Code | OS |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000410_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| Gene deletion | TP53 | - | Homozygous | 2 out of 3 copies | from parent cell line HL-60 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
Fogh J., Wright W.C., Loveless J.D.
J. Natl. Cancer Inst. 58:209-214(1977).
p53 functions as a cell cycle control protein in osteosarcomas.";
Bressac B., Ozturk M., Baker S.J., Vogelstein B., Friend S.H.
Mol. Cell. Biol. 10:5772-5781(1990).
Rearrangement of the p53 gene in human osteogenic sarcomas.";
Masuda H., Miller C., Koeffler H.P., Battifora H.A., Cline M.J.
Proc. Natl. Acad. Sci. U.S.A. 84:7716-7719(1987).
Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties.
Bar-Shavit Z., Shull S., Mann K., Rodan G.A.
Cancer Res. 47:4961-4966(1987).
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
Wright W.C., Daniels W.P., Fogh J.
J. Natl. Cancer Inst. 66:239-247(1981).
HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.
J. Natl. Cancer Inst. 66:1003-1012(1981).
Immunostaining of the p30/32MIC2 antigen and molecular detection of EWS rearrangements for the diagnosis of Ewing's sarcoma and peripheral neuroectodermal tumor.
Lollini P.-L., Picci P., Bertoni F., Baldini N.
Hum. Pathol. 27:408-416(1996).
A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies.
Jia S.-F., Worth L.L., Kleinerman E.S.
Clin. Exp. Metastasis 17:501-506(1999).
Short tandem repeat profiling provides an international reference standard for human cell lines.
Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.
Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
Chromosomal alterations in osteosarcoma cell lines revealed by comparative genomic hybridization and multicolor karyotyping.
Poremba C.
Cancer Genet. Cytogenet. 140:145-152(2003).
Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3.
Gabbert H.E., Poremba C.
Cancer Res. 64:3395-3405(2004).
Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts.
Milz S.
Anticancer Res. 24:3743-3748(2004).
Phenotypic instability of Saos-2 cells in long-term culture.";
Hausser H.-J., Brenner R.E.
Biochem. Biophys. Res. Commun. 333:216-222(2005).
Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53.
Tercero J.C., Piris M.A., Jimeno J.M., Carnero A.
J. Cell. Biochem. 100:339-348(2007).
Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.
Myklebost O.
Int. J. Cancer 121:199-205(2007).
Levels of p27(kip1) determine Aplidin sensitivity.";
Diaz-Uriarte R., Aracil M., Tercero J.C., Jimeno J.M., Carnero A.
Mol. Cancer Ther. 6:1310-1316(2007).
Identification of cryptic microaberrations in osteosarcoma by high-definition oligonucleotide array comparative genomic hybridization.
Squire J.A., Zielenska M.
Cancer Genet. Cytogenet. 179:52-61(2007).
Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.
Buerger H., Aigner T., Gabbert H.E., Poremba C.
Genes Chromosomes Cancer 49:40-51(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Functional characterization of osteosarcoma cell lines provides representative models to study the human disease.
Hogendoorn P.C.W., Llombart-Bosch A., Cleton-Jansen A.-M.
Lab. Invest. 91:1195-1205(2011).
Genetically modified T cells targeting interleukin-11 receptor alpha-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases.
Huang G.-X., Yu L., Cooper L.J.N., Hollomon M., Huls H., Kleinerman E.S.
Cancer Res. 72:271-281(2012).
Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma.
Myklebost O., Meza-Zepeda L.A.
PLoS ONE 7:E48262-E48262(2012).
A novel approach for characterizing microsatellite instability in cancer cells.
Lu Y.-H., Soong T.D., Elemento O.
PLoS ONE 8:E63056-E63056(2013).
Levels of active tyrosine kinase receptor determine the tumor response to Zalypsis.
Aviles P., Santamaria G., Tercero J.C., Cuevas C., Carnero A.
BMC Cancer 14:281.1-281.10(2014).
Establishment and characterization of a new highly metastatic human osteosarcoma cell line derived from Saos2.
Du L., Fan Q.-M., Tu B., Yan W., Tang T.-T.
Int. J. Clin. Exp. Pathol. 7:2871-2882(2014).
Characterization of the metastatic phenotype of a panel of established osteosarcoma cells.
Luu H.H., Meltzer P.S., Khanna C.
Oncotarget 6:29469-29481(2015).
Sarcoma cell line screen of oncology drugs and investigational agents identifies patterns associated with gene and microRNA expression.
Harris E., Monks A., Morris J.
Mol. Cancer Ther. 14:2452-2462(2015).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
Positively selected enhancer elements endow osteosarcoma cells with metastatic competence.
Versteeg H.H., Stamatoyannopoulos J.A., Khanna C., Scacheri P.C.
Nat. Med. 24:176-185(2018).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
Sellers W.R., Gygi S.P.
Cell 180:387-402.e16(2020).